Baptiste Delapierre

Avenue De La Côte De Nacre
Caen, 14000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Bruton's tyrosine kinase inhibitors and cardiovascular risk: a meta-analysis.

Bruton's tyrosine kinase inhibitors and cardiovascular risk: a meta-analysis.

Journal: European heart journal

Published: December 18, 2025

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Journal: Haematologica

Published: November 06, 2025

Large B-cell lymphoma: The LYSA pragmatic guidelines.

Large B-cell lymphoma: The LYSA pragmatic guidelines.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 21, 2025

Outcomes on peritoneal dialysis in patients with primary kidney disease related to multiple myeloma: A cohort study with data from the French Language Peritoneal Dialysis Registry.

Outcomes on peritoneal dialysis in patients with primary kidney disease related to multiple myeloma: A cohort study with data from the French Language Peritoneal Dialysis Registry.

Journal: Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis

Published: July 09, 2025

Association Between the Renin-Angiotensin System and Ibrutinib-Related Cardiovascular Adverse Events: A Translational Cohort Study.

Association Between the Renin-Angiotensin System and Ibrutinib-Related Cardiovascular Adverse Events: A Translational Cohort Study.

Journal: Biomedicines

Published: June 04, 2025

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.

Clinical benefit of tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: real-world data from the EarlyMIND study.

Journal: Haematologica

Published: December 10, 2024

Implementation of initial pharmaceutical consultations and follow-up in onco-hematology: Two years review and outlooks

Implementation of initial pharmaceutical consultations and follow-up in onco-hematology: Two years review and outlooks

Journal: Annales pharmaceutiques francaises

Published: August 28, 2024

Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance database.

Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance database.

Journal: Leukemia

Published: July 02, 2024

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.

Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.

Journal: Blood advances

Published: July 08, 2022

Role of social status and social environment on net survival in patients with chronic lymphocytic leukemia: A high-resolution population-based study.

Role of social status and social environment on net survival in patients with chronic lymphocytic leukemia: A high-resolution population-based study.

Journal: Cancer epidemiology

Published: June 16, 2022

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers.

Journal: Bone marrow transplantation

Published: September 15, 2019

Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.

Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.

Journal: Current research in translational medicine

Published: December 21, 2018

Showing 1-12 of 12

Last Updated: 09/26/2026